MedTrace Logo

Unicondylar Knee Arthroplasty Versus Total Knee Arthroplasty in Patients With Anteromedial Osteoarthritis of the Knee

NCT02430129 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2025-03-13

No results posted yet for this study

Summary

This study is a randomized controlled trial comparing total knee arthroplasty (TKA) to unicompartmental knee arthroplasty (UKA) in patients with no to moderate anteromedial knee osteoarthritis. TKA patients will receive the Zimmer Persona (Warsaw, IN) posterior cruciate retaining total knee arthroplasty, while UKA patients will receive the Biomet Oxford (Warsaw, IN) mobile bearing unicompartmental knee arthroplasty.

Outcome measures will include Western Ontario and McMaster University Osteoarthritis Index (WOMAC) and Oxford Knee Score (OKS) questionnaires, as well as biomechanics and EMG analysis from the investigating gait lab.

The investigators hypothesize that post-operative UKA patients will display higher clinical scores using WOMAC and OKS questionnaires, and superior biomechanical analysis measures. The investigators further hypothesize that the biomechanics data will assist in the understanding of the outcome score differential both pre- and post-operatively in both groups, as well as between-groups.

Total follow up period will be two years.

Conditions

Interventions

PROCEDURE

Total knee arthroplasty

Zimmer Persona posterior cruciate retaining total knee arthroplasty (ZImmer, Warsaw, IN)

PROCEDURE

Unicompartment knee arthroplasty

Biomet Oxford mobile-bearing unicompartmental knee arthroplasty (Biomet, Warsaw, IN)

DEVICE

Persona

Zimmer Persona posterior cruciate retaining total knee arthroplasty (ZImmer, Warsaw, IN)

DEVICE

Oxford

Biomet Oxford mobile-bearing unicompartmental knee arthroplasty (Biomet, Warsaw, IN)

Sponsors & Collaborators

  • Alberta Hip and Knee Clinic

    lead OTHER

Principal Investigators

  • Kelly D Johnston, MD · University of Calgary Cumming School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02430129 on ClinicalTrials.gov